LLY

1,127.49

-0.31%↓

JNJ

233.13

-1.8%↓

ABBV

220.76

-0.61%↓

UNH

409.07

-0.34%↓

MRK

114.02

-1.81%↓

LLY

1,127.49

-0.31%↓

JNJ

233.13

-1.8%↓

ABBV

220.76

-0.61%↓

UNH

409.07

-0.34%↓

MRK

114.02

-1.81%↓

LLY

1,127.49

-0.31%↓

JNJ

233.13

-1.8%↓

ABBV

220.76

-0.61%↓

UNH

409.07

-0.34%↓

MRK

114.02

-1.81%↓

LLY

1,127.49

-0.31%↓

JNJ

233.13

-1.8%↓

ABBV

220.76

-0.61%↓

UNH

409.07

-0.34%↓

MRK

114.02

-1.81%↓

LLY

1,127.49

-0.31%↓

JNJ

233.13

-1.8%↓

ABBV

220.76

-0.61%↓

UNH

409.07

-0.34%↓

MRK

114.02

-1.81%↓

Search

10X Genomics Inc (Class A)

Closed

SectorHealthcare

32.42 9.38

Overview

Share price change

24h

Current

Min

28.8

Max

32.32

Key metrics

By Trading Economics

Income

2.8M

-13M

Sales

-15M

151M

EPS

0.07

Profit margin

-8.93

Employees

1,178

EBITDA

2.5M

-17M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-15.05% downside

Dividends

By Acuity

Next Earnings

6 Aug 2026

Market Stats

By TradingEconomics

Market Cap

1.1B

3.9B

Previous open

23.04

Previous close

32.42

News Sentiment

By Acuity

50%

50%

162 / 342 Healthcare

10X Genomics Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

About 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat